| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Zhong P et al. | αβ Integrin-targeted reduction-sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo. | 2017 | J Control Release | pmid:27986551 |
| Adams SR et al. | Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. | 2016 | Nat Commun | pmid:27698471 |
| Mahtani RL and Vogel CL | When Can a Salvage Therapy (T-DM1) Take the Lead? | 2016 | J. Clin. Oncol. | pmid:27432926 |
| Bergamini A et al. | Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer. | 2016 | Expert Opin Investig Drugs | pmid:27797594 |
| Zhong P et al. | Glutathione-Sensitive Hyaluronic Acid-SS-Mertansine Prodrug with a High Drug Content: Facile Synthesis and Targeted Breast Tumor Therapy. | 2016 | Biomacromolecules | pmid:27723970 |
| Le QA et al. | Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. | 2016 | Breast Cancer Res. Treat. | pmid:27572338 |
| Eckelmann D et al. | Occurrence and spatial distribution of maytansinoids in Putterlickia pyracantha, an unexplored resource of anticancer compounds. | 2016 | Fitoterapia | pmid:27521896 |
| Chen Y et al. | Structural Characterization of Cross-Linked Species in Trastuzumab Emtansine (Kadcyla). | 2016 | Bioconjug. Chem. | pmid:27458087 |
| Li C et al. | Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. | 2016 | Cancer Chemother. Pharmacol. | pmid:27423671 |
| Chen L et al. | In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. | 2016 | MAbs | pmid:27380163 |
| Géraud A et al. | Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. | 2016 | Cancer Radiother | pmid:27342941 |
| Frenel JS et al. | [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases]. | 2016 | Bull Cancer | pmid:26992855 |
| Lanshoeft C et al. | Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry. | 2016 | Rapid Commun. Mass Spectrom. | pmid:26969923 |
| Shah MH et al. | Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. | 2016 | Invest New Drugs | pmid:26961907 |
| Dillon RL et al. | Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. | 2016 | J. Immunother. | pmid:26938945 |
| Kashiwaba M et al. | A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. | 2016 | Jpn. J. Clin. Oncol. | pmid:26917603 |
| Squires H et al. | Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. | 2016 | Pharmacoeconomics | pmid:26892972 |
| Jerjian TV et al. | Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. | 2016 | Pharmacotherapy | pmid:26799352 |
| Heudi O et al. | Quantitative analysis of maytansinoid (DM1) in human serum by on-line solid phase extraction coupled with liquid chromatography tandem mass spectrometry - Method validation and its application to clinical samples. | 2016 | J Pharm Biomed Anal | pmid:26771131 |
| de Vries CL et al. | Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1. | 2016 | J. Neurooncol. | pmid:26732082 |
| Elsada A et al. | NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer. | 2016 | Lancet Oncol. | pmid:26703893 |
| Luo Q et al. | Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate. | 2016 | Anal. Chem. | pmid:26629796 |
| Venkatesan P | Trastuzumab emtansine for HER2-positive breast cancer. | 2016 | Lancet Oncol. | pmid:27866859 |
| Nonagase Y et al. | Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. | 2016 | Oncotarget | pmid:27768588 |
| Gebhart G et al. | Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. | 2016 | Ann. Oncol. | pmid:26598545 |
| Milowsky MI et al. | Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. | 2016 | Urol. Oncol. | pmid:27765518 |
| Fan Y et al. | Enhancement of UDPG synthetic pathway improves ansamitocin production in Actinosynnem pretiosum. | 2016 | Appl. Microbiol. Biotechnol. | pmid:26585444 |
| Walles M et al. | New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats. | 2016 | Drug Metab. Dispos. | pmid:27122302 |
| Li S et al. | Constitutive overexpression of asm18 increases the production and diversity of maytansinoids in Actinosynnema pretiosum. | 2016 | Appl. Microbiol. Biotechnol. | pmid:26572523 |
| Ogitani Y et al. | DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. | 2016 | Clin. Cancer Res. | pmid:27026201 |
| Roviello G et al. | Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. | 2016 | Tumour Biol. | pmid:26566626 |
| Baselga J et al. | Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. | 2016 | Clin. Cancer Res. | pmid:26920887 |
| Zhang YG et al. | Nocardiopsis ansamitocini sp. nov., a new producer of ansamitocin P-3 of the genus Nocardiopsis. | 2016 | Int. J. Syst. Evol. Microbiol. | pmid:26486850 |
| Sibaud V et al. | T-DM1 extravasation: first description. | 2016 | J Eur Acad Dermatol Venereol | pmid:25879278 |
| Force J et al. | Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. | 2016 | J. Clin. Oncol. | pmid:24778392 |
| Ponte JF et al. | Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. | 2016 | Neoplasia | pmid:27889646 |
| Hassan R et al. | Mesothelin Immunotherapy for Cancer: Ready for Prime Time? | 2016 | J. Clin. Oncol. | pmid:27863199 |
| Kim SB et al. | Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. | 2016 | Int. J. Cancer | pmid:27428671 |
| Mitsuya K et al. | Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases. | 2016 | BMC Cancer | pmid:27377061 |
| Cilliers C et al. | Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. | 2016 | AAPS J | pmid:27287046 |
| Martin M and López-Tarruella S | Emerging Therapeutic Options for HER2-Positive Breast Cancer. | 2016 | Am Soc Clin Oncol Educ Book | pmid:27249772 |
| Singh R et al. | A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. | 2016 | Mol. Cancer Ther. | pmid:27197308 |
| Bellat V et al. | Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties. | 2016 | Biomacromolecules | pmid:27180972 |
| Ogitani Y et al. | Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. | 2016 | Cancer Sci. | pmid:27166974 |
| Feng L et al. | Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. | 2016 | J. Exp. Clin. Cancer Res. | pmid:27102688 |
| T-DM1 Combo Graduates from I-SPY 2. | 2016 | Cancer Discov | pmid:27095360 | |
| Singh AP et al. | Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). | 2016 | AAPS J | pmid:27029797 |
| Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate. | 2016 | Cancer Discov | pmid:26701087 | |
| T-DM1 Extends Survival in HER2+ Breast Cancer. | 2016 | Cancer Discov | pmid:26676162 | |
| Askoxylakis V et al. | Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. | 2016 | J. Natl. Cancer Inst. | pmid:26547932 |